What's new

EMEA-002582-PIP03-23

EMEA-002582-PIP03-23

Mar 17, 2025 - 11:58
 0
EMEA-002582-PIP03-23
EMEA-002582-PIP03-23
Read More

Tags:

Previous Article

NaaS Technology Inc. and Xiaomi Auto join forces to enhance smart EV charging ec...

Next Article

CONTEXT Forecast: European IT distribution market to grow 3.6% in 2025

Related Posts

Opinion/decision on a Paediatric investigation plan (PIP): Enerzair Breezhaler, Indacaterol (acetate),Mometasone (furoate),Glycopyrronium bromide, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Pneumology-allergology, PIP number: P/0493/2023

Opinion/decision on a Paediatric investigation plan (PI...

Feb 15, 2025  0

Mandatory use of ISO/ICH E2B(R3) individual case safety reporting in the EU: hands-on training course using the EudraVigilance system, Online, European Medicines Agency, Amsterdam, the Netherlands, from 12 May 2025 to 16 May 2025

Mandatory use of ISO/ICH E2B(R3) individual case safety...

Feb 14, 2025  0

Human medicines European public assessment report (EPAR): Xtandi, enzalutamide, Date of authorisation: 21/06/2013, Date of refusal: 26/04/2013, Revision: 26, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 25, 2025  0